Serono Discontinues Trial Programs
Serono announced the discontinuation of two phase 3 clinical trial programs; onercept (recombinant tumor necrosis factor binding protein) in moderate-to-severe…
network
Serono announced the discontinuation of two phase 3 clinical trial programs; onercept (recombinant tumor necrosis factor binding protein) in moderate-to-severe…